What is the 13F Pro Quality Score for BMRA?

13F Pro ranks BIOMERICA INC (BMRA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BMRA's current score at https://13fpro.ai/research/BMRA (free sign-up required for the full ranking).

Where does 13F Pro source BMRA data?

All BIOMERICA INC fundamentals and ownership data come directly from SEC EDGAR. BIOMERICA INC files with the SEC under CIK 73290. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BMRA in?

BIOMERICA INC (BMRA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BMRA research updated on 13F Pro?

BMRA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BIOMERICA INC(BMRA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 73290 BMRA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $18.9M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

BMRA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BIOMERICA INC (BMRA), a Healthcare sector company. BMRA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $18.9m in revenue. Based on the latest XBRL financial filings (Q3 2026), BIOMERICA INC reports quarterly revenue of $987.0K, net income of $-1.3M, free cash flow of $-1.3M. Top institutional holders of BMRA by reported 13-F value include GEODE CAPITAL MANAGEMENT,, BlackRock,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. BMRA trades on the Nasdaq exchange and files with the SEC under CIK 73290. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BMRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIOMERICA INC directly from SEC EDGAR.

Revenue

Q3 2026

$987.0K

Net Income

Q3 2026

$-1.3M

Free Cash Flow

Q3 2026

$-1.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-1.9% YoY

$5.3MFY 2025

FY22 $18.9MFY23 $5.3MFY24 $5.4MFY25 $5.3M

Net Income

+16.8% YoY

$-5.0MFY 2025

FY22 $-4.5MFY23 $-7.1MFY24 $-6.0MFY25 $-5.0M

Operating Income

+19.3% YoY

$-5.1MFY 2025

FY22 $-4.5MFY23 $-7.2MFY24 $-6.4MFY25 $-5.1M

EPS (Diluted)

+23.9% YoY

$-2.16FY 2025

FY22 $-0.36FY23 $-0.50FY24 $-2.84FY25 $-2.16

Total Assets

-35.8% YoY

$5.9MFY 2025

FY22 $11.4MFY23 $14.5MFY24 $9.3MFY25 $5.9M

Op. Cash Flow

+28.4% YoY

$-3.8MFY 2025

FY22 $-479.0KFY23 $-5.5MFY24 $-5.4MFY25 $-3.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2018
Revenue	$5.3M -1.9%	$5.4M +1.4%	$5.3M -71.7%	$18.9M +162.1%	$7.2M +29.4%	$5.6M
Net Income	$-5.0M +16.8%	$-6.0M +16.3%	$-7.1M -57.6%	$-4.5M +39.2%	$-7.4M -408.0%	$-1.5M
Operating Income	$-5.1M +19.3%	$-6.4M +11.9%	$-7.2M -59.3%	$-4.5M +39.5%	$-7.5M -406.1%	$-1.5M
EPS (Diluted)	$-2.16 +23.9%	$-2.84 -468.0%	$-0.50 -38.9%	$-0.36 +41.9%	$-0.62 -264.7%	$-0.17
Total Assets	$5.9M -35.8%	$9.3M -36.0%	$14.5M +27.1%	$11.4M -3.8%	$11.8M +126.3%	$5.2M
Operating Cash Flow	$-3.8M +28.4%	$-5.4M +2.1%	$-5.5M -1042.8%	$-479.0K +90.9%	$-5.3M -347.3%	$-1.2M

AI Insight: BMRA Financial Trends

BMRA burns equity quarter after quarter with no revenue growth, shrinking book value from $7M to $3M over eight quarters.

• Revenue stagnated at $1M–$2M across all eight quarters with no discernible growth trajectory.

• Equity has eroded from $7M in Q2 2024 to $3M in Q1 2026, a 57% decline over eight quarters.

• Operating income remained negative every quarter, ranging from -$1M to -$2M, with no improvement trend.

⚠ Equity at $3M in Q1 2026 — continued losses at this rate could exhaust book value within 3–4 quarters.

⚠ Operating cash outflow persisted every quarter; no debt reported, but liquidity runway warrants close monitoring.

AI Insight: BMRA Ratio Trends

BIOMERICA remains deeply loss-making with operating margins worsening to -131.4% in Q1 2026, erasing a brief Q4 2024 improvement.

• Operating margin briefly improved from -136.9% in Q2 2024 to -60.8% in Q4 2024, but has since deteriorated sharply to -131.4% in Q1 2026.

• ROE plunged to -158.2% in Q1 2026 from -74.3% in Q4 2024, signaling accelerating equity erosion.

• Q3 2025 showed a fleeting near-breakeven NPM of 0.1% and ROE of 0.2%, but Q4 2025 and Q1 2026 saw an immediate reversal.

⚠ NPM collapsed from 0.1% in Q3 2025 to -109.1% in Q4 2025 and -132.8% in Q1 2026 — the Q3 2025 inflection was not sustained.

⚠ ROA of -87.5% in Q4 2025 suggests asset base is generating severe losses; Q1 2026 ROA data is absent, obscuring the latest position.

⚠ D/E data is unavailable across all periods, leaving leverage and balance-sheet risk unquantifiable.

Get alerted when BMRA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BIOMERICA INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BMRA

GEODE CAPITAL MANAGEMENT, LLC
$118.3K56,042 sh
BlackRock, Inc.
$39.5K18,636 sh
VANGUARD CAPITAL MANAGEMENT LLC
$30.6K14,514 sh
LPL Financial LLC
$23.0K10,849 sh
VANGUARD FIDUCIARY TRUST CO
$14.0K6,613 sh
HOLLENCREST SECURITIES LLC
$1.7K825 sh
UBS Group AG
$1.1K519 sh
HARBOUR INVESTMENTS, INC.
$265.00125 sh
MCF Advisors LLC
$13.006 sh
DANSKE BANK A/S
$2.001 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$118.3K	56,042
BlackRock, Inc.	$39.5K	18,636
VANGUARD CAPITAL MANAGEMENT LLC	$30.6K	14,514
LPL Financial LLC	$23.0K	10,849
VANGUARD FIDUCIARY TRUST CO	$14.0K	6,613
HOLLENCREST SECURITIES LLC	$1.7K	825
UBS Group AG	$1.1K	519
HARBOUR INVESTMENTS, INC.	$265.00	125
MCF Advisors LLC	$13.00	6
DANSKE BANK A/S	$2.00	1

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BMRA on your watchlist

Track score changes the day BIOMERICA INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BMRA a good stock to buy?

13F Pro's AI-powered analysis of BIOMERICA INC (BMRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BMRA are available on the BMRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BMRA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BMRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BIOMERICA INC's investment landscape.